BioCentury | May 21, 2020
Product Development

May 20 Quick Takes: Filgotinib meets in ulcerative colitis; broader labels for Lynparza, Tecentriq, plus updates from Eiger, eGenesis and more

High dose filgotinib meets ulcerative colitis endpoints A 200 mg dose of filgotinib from Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) met the primary endpoints in the placebo-controlled Phase IIb/III SELECTION trial to...
BioCentury | Dec 28, 2019
Financial News

Elpiscience’s $100M series B provides path to IPO

Elpiscience hopes a $100 million series B round led by Hyfinity Investments will enable the company to expand its immuno-oncology pipeline and provide enough runway to carry it to an IPO, Ming Fang, head of...
BioCentury | May 24, 2019
Preclinical News

May 24 Preclinical Quick Takes: Baker-Garcia team controls cytokine receptor signaling; plus data from Surface, Innate, Moderna and Lyvgen

Cytokine mimics permit control of dimer receptor signaling David Baker and Christopher Garcia's University of Washington-Stanford University team has created cytokine mimetics -- symmetric compounds for tunable control of cytokine receptor signaling. In a proof-of-concept...
BioCentury | Mar 7, 2019
Translation in Brief

Blocking B cell vesicles to enhance chemotherapy

Blocking extracellular vesicles derived from B cells could offer a new therapeutic avenue to enhance the efficacy of chemotherapy for cancer, according to a Zhejiang University study. Chemotherapy reduces antitumor immunity by inducing systemic immunosuppression....
BioCentury | Jan 11, 2019
Finance

Exscientia looks inward

After spending six years building its artificial intelligence drug discovery platform and working with pharma partners, Exscientia Ltd. aims to use the bulk of the $26 million raised in a series B round to build...
BioCentury | Dec 21, 2018
Company News

Surface drops after deprioritizing lead product

Surface Oncology Inc. (NASDAQ:SURF) was off $3.52 (48%) to $3.89 on Dec. 19 after the company said late Dec. 18 it will deprioritize Phase I candidate SRF231, one of its two clinical programs. The immunotherapy...
BioCentury | Dec 19, 2018
Company News

Surface drops after deprioritizing lead product

Surface Oncology Inc. (NASDAQ:SURF) was off $3.52 (48%) to $3.89 on Wednesday after the company said late Tuesday it will deprioritize Phase I candidate SRF231, one of its two clinical programs. The immunotherapy company said...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BioCentury | Nov 1, 2018
Emerging Company Profile

Secarna’s next-gen oligos

Secarna Pharmaceuticals GmbH’s antisense oligonucleotides for immuno-oncology could have better tissue penetration than small molecules and antibodies against the same targets. The company was established in 2015 by the founders and investors who launched antisense...
BioCentury | Oct 26, 2018
Company News

AstraZeneca gets rights, options to Innate immuno-oncology therapies

AstraZeneca plc (LSE:AZN; NYSE:AZN) expanded its next generation immuno-oncology pipeline on Oct. 23, gaining rights and options to a basket of therapies from Innate Pharma S.A. (Euronext:IPH). In return, Innate gained U.S. and European commercialization...
Items per page:
1 - 10 of 22